Le Lézard
Classified in: Health
Subject: MRR

Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033


HARTFORD, Conn., April 16, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title:

THELANSIS LOGO

Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Asthma is a chronic inflammatory respiratory disease, which affects adults as well as pediatrics. In the United States, it affects approximately 25 million people, including 5 million children/adolescents. About 1 million asthmatic people in the United States get hospitalized each year. Globally, asthma impacts more than 250 million people, reflecting high disease burden. In addition to the age-group, asthma patients can be categorized into mild, moderate or severe patients, based on the disease severity and the treatment required to achieve good asthma control.

Established medications for asthma management include rescue therapies (e.g., SABA) and maintenance therapies, such as the fixed-dose combinations (FDCs) of LABA/ICS. The brand share for LABA/ICS is eroding rapidly in the asthma market because of the launches of several generics (including authorized generics) in the recent years in the major markets. Nevertheless, newer therapies, for example, biologics have been particularly effective for moderate to severe, uncontrolled asthma patients and have been gaining inroads for these patients. Spiriva, Nucala, Fasenra, Cinqair, Dupixent, and Tezspire are the useful treatment options for refractory asthma, as per interviewed KOLs. Many of these drugs offer improved patient adherence because of their less-frequent administration schedules.

Even with the availability of these newer therapies, several opportunities exist to target niche patient segments in asthma (e.g., non-TH2 asthma) and to develop more convenient FDC formulations, among other opportunities. Successfully targeting one or more of the unmet needs would be a differentiating factor for a novel emerging drug in asthma, and would enable faster sales and patient share uptake in the asthma market. Some promising emerging agents in asthma include,

Emerging agent

Developer

Target unmet need

Phase of development

Breztri (a LABA/LAMA/ICS triple FDC)

AstraZeneca

Better patient compliance

Phase III

Depemokinab (a longer-acting IL-5 antagonist)

GlaxoSmithKline

Better patient compliance

Phase III

Masitinib (a selective tyrosine kinase inhibitor)

AB Science

Targets both eosinophilic and non-eosinophilic severe asthma

Phase III

 

KOL perspectives:

"The emerging triple FDCs will definitely offer more convenience to patients. However, many patients may not be their candidates because they don't necessarily need three drugs at a given point of time to control asthma." - A leading U.S.-based pulmonologist

"The hardest thing would be to offer a cure for asthma. We are very far from reaching that. I believe we have a good number of anti-inflammatory drugs, including biologics. Perhaps, we need some more for specific refractory patients. Now, it's the time to move the needle for developing drugs toward curing asthma."  - A leading Europe-based pulmonologist

Key business insights:

Thelansis's Asthma report provides in-depth insights on the epidemiology and the drug development pipeline for the various target patient segments in asthma. In addition, the report answers key questions such as,

About Thelansis

Thelansis specializes in pharmaceutical and biopharmaceutical business research and consulting Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indications. Over the period, we have built a strong repository of 6,000+ Bio-pharma reports which essentially cover Epidemiology studies and Market forecasting, opportunity assessment based on the KOL Interviews and conference coverage. Competitive intelligence and conference coverage throughout the phases of asset development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Offerings in the respiratory / asthma space: syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, consulting, and payer insights.

The drug developers can engage Thelansis for customized market research and can gain on possible solutions for ensuring considerable market penetration for their respective therapies.

Contact us today on ....

Website:  Thelansis.com

Chinmaya Kumar Senapati

Email- [email protected]

Contact No.-+91-6397349664

Logo: https://mma.prnewswire.com/media/2336260/THELANSIS_LOGO.jpg

SOURCE Thelansis Knowledge Partners LLP


These press releases may also interest you

at 12:05
Valar Labs, the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing. The funding follows Valar Labs' completion of a recent international, multi-institution...

at 12:03
The U.S. Food and Drug Administration reached a significant milestone with approval of its reorganization involving the creation of a unified Human Foods Program (HFP), adoption of a new model for its field operations and other significant...

at 12:00
L'OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic recycling, the result of a European circular economy CARBIOS, L'OCCITANE en Provence and Pinard Beauty Pack join forces to establish an efficient European value chain for...

at 12:00
Starting June 11, New Hampshire Fishercats and University of New Hampshire in Manchester, NH will host the All of Us Journey, a traveling educational exhibit that brings the National Institutes of Health's All of Us Research Program to communities...

at 12:00
Starting June 11, Cedars Sinai, Mexican American Opportunity Foundation, National Alliance for Hispanic Health, PRIDENet, in California will host the All of Us Journey, a traveling educational exhibit that brings the National Institutes of Health's...

at 12:00
Virrtue, a rapidly growing finance & accounting BPO company, announced today their acquisition of tech-driven accounting services company Virgate. Headquartered in Gloucester, England, Virgate is a trusted partner to businesses across the UK and...



News published on and distributed by: